Anupam Rasayan India

Anupam Rasayan reported a strong FY26 with consolidated revenue of ₹2,384 croreCurrent reported value: ₹2,384 crore. No comparable prior figure is available in the source record. (+65Current reported value: 65. No comparable prior figure is available in the source record.% YoY) and EBITDA of ₹543 croreCurrent reported value: ₹543 crore. No comparable prior figure is available in the source record. (+32% YoY), driven by robust execution across agrochemicals, pharma, and performance materials. The company's diversification strategy reduced agro dependence from 76% in FY22Current reported value: 22. No comparable prior figure is available in the source record. to 55% in FY26. Operating cash flow improved to ₹334 croreCurrent reported value: ₹334 crore. No comparable prior figure is available in the source record. on better working capital management. Management guided for 20-30%Current 30%. Reported change: N/A. standalone revenue growth over 3-5 years, supported by a ₹14,000 crore order bookCurrent ₹14,000 crore order book. Reported change: N/A.. Key strategic moves include the acquisition of JHawk Fine Chemicals (US) and a definitive agreement to acquire 43.3-48.5% of Bliss GVS Pharma, creating a full pharma platform. No major capex is planned beyond maintenance. Risk: Integration of multiple acquisitions may strain management bandwidth and execution.